Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company that develops innovative precision medicines for serious, unmet medical needs in oncology. The company focuses on creating drug candidates in the precision medicine field, basing its selection and clinical development processes on scientific data regarding cancer-promoting factors, clinical landscape understanding, and regulatory requirements. Nuvectis Pharma, Inc. was incorporated in July 2020 in Delaware as Centry Pharma, Inc., changing its name in July 2021. Its office is located at 1 Bridge Plaza, 2nd Floor, Fort Lee, NJ 07024. The company's primary product under development is NXP900. In August 2021, Nuvectis Pharma licensed worldwide commercial rights for NXP900 from the University of Edinburgh in Scotland. NXP900 is a targeted-therapy, small molecule drug candidate designed to inhibit the proto-oncogene c-Src ("SRC") and YES1 kinases, which are key members of the SRC kinase family. In May 2023, the U.S. Food and Drug Administration ("FDA") cleared the Investigational New Drug application ("IND") for NXP900, which included a Phase 1 protocol consisting of a dose-escalation Phase 1a and an expansion Phase 1b.